Harvard Bioscience (HBIO) to Release Quarterly Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) will be posting its quarterly earnings results on Tuesday, April 23rd.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $28.15 million during the quarter, compared to analyst estimates of $27.80 million. Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%.

Harvard Bioscience Price Performance

Shares of NASDAQ HBIO opened at $3.70 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.92 and a current ratio of 1.85. Harvard Bioscience has a one year low of $3.69 and a one year high of $6.29. The firm has a market capitalization of $160.58 million, a P/E ratio of -46.24 and a beta of 1.42. The company’s fifty day moving average is $4.32 and its two-hundred day moving average is $4.50.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA increased its stake in Harvard Bioscience by 47.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 3,200 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Harvard Bioscience during the 2nd quarter worth $37,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Harvard Bioscience in the 3rd quarter worth about $40,000. Barclays PLC acquired a new stake in Harvard Bioscience in the 2nd quarter valued at about $43,000. Finally, Lazard Asset Management LLC increased its holdings in Harvard Bioscience by 230.5% during the 1st quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 4,966 shares in the last quarter. 80.87% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.